Next-generation sequencing and epigenome technologies: Potential medical applications

Expert Review of Medical Devices

Volumn 7, Issue 6, 2010, Pages 723-726

  Roukos, Dimitrios H ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

cancer genome; epigenome; genetic tests; human genome; innovation; medical implications; NGS technology; validity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

BREAST CANCER; CANCER GENETICS; DNA METHYLATION; EDITORIAL; EPIGENETICS; EPIGENOME; EPIGENOMICS; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC SCREENING; GENOME; GENOME ANALYSIS; GENOMICS; HUMAN GENOME; NONLINEAR SYSTEM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER;

BIOTECHNOLOGY; CHROMOSOME MAPPING; EPIGENOMICS; FORECASTING; GENETIC TESTING; HUMANS; SEQUENCE ANALYSIS, DNA;

EID: 78149381840     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.10.68     Document Type: Editorial

References (44)

1. The human genome at ten. Nature 464(7289), 649-650 (2010).
2. Collins F. Has the revolution arrived? Nature 464(7289), 674-675 (2010).
3. Venter JC. Multiple personal genomes await. Nature 464(7289), 676-677 (2010).
4. Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
5. Check Hayden E. Human genome at ten: life is complicated. Nature 464(7289), 664-667 (2010).
6. ENCODE Project Consortium, Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, ingeras TR, Margulies EH. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447(7146), 799-816 (2007).
7. Human genome at ten: the sequence explosion. Nature 464(7289), 670-671 (2010).
8. Check Hayden E. 10,000 genomes to come. Nature 462(7269), 21 (2009).
9. International Cancer Genome Consortium: international network of cancer genome projects. Nature 464, 993-998 (2010).
10. Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464(7291), 999-1005 (2010).
11. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465(7297), 473-477 (2010).
12. Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463(7278), 191-196 (2010).
13. Ledford H. Big science: the cancer genome challenge. Nature 464(7291), 972-974 (2010).
14. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 458(7239), 719-724 (2009).
15. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat. Rev. Clin. Oncol. 7(9), 493-507 (2010).
16. Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 458(7236), 290-292 (2009).
17. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9(7), 463-475 (2009).
18. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353(16), 1734-1736 (2005).
19. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and metaanalysis of randomized controlled trials. Oncologist 13(6), 620-630 (2008).
20. Goldhirsch A, Ingle JN, Gelber RD et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329 (2009).
21. Jenkintown PA. National Comprehensive Cancer Network. Guidelines for treatment of cancer by site. National Comprehensive Cancer Network (2009).
22. Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8), 1039-1043 (2010).
23. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
24. van Cutsem E, Kang Y, Chung H et al. Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J. Clin. Oncol. 27(Suppl.), 18s (2009) (Abstract LBA4509).
25. Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann. Surg. Oncol. 17, 14-17 (2010).
26. Roukos DH. Bionetworks-based personalized medicine versus comparativeeffectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn. 10(3), 247-250 (2010).
27. Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3), 283-287 (2010).
28. Donnelly P. Progress and challenges in genome-wide association studies in humans. Nature 456, 728-731 (2008).
29. Manolio TA. Genome-wide association studies and assessment of the risk of disease. N. Engl. J. Med. 363(2), 166-176 (2010).
30. Beaudet AL. Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 466(7308), 816-817 (2010).
31. Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N. Engl. J. Med. DOI: 10.1056/NEJMp1006202 (2010) (Epub ahead of print).
32. Annes JP, Giovanni MA, Murray MF. Risks of presymptomatic direct-to-consumer genetic testing. N. Engl. J. Med. DOI: 10.1056/NEJMp1006029 (2010) (Epub ahead of print).
33. Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark. Med. 4(4), 583-586 (2010).
34. Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Personalized. Med. 7(4), 347-350. DOI 10.2217/ PME.10.30 (2010) (Epub ahead of print).
35. Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn. 10(5), 541-545 (2010).
36. Fraga MF, Ballestar E, Paz MF et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102, 10604-10609 (2005).
37. Time for the epigenome. Nature 463(7281), 587 (2010)
38. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358(11), 1148-1159 (2008).
39. Katsnelson A. Genomics goes beyond DNA sequence. Nature 465(7295), 145 (2010).
40. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 461(7261), 218-223 (2009).
41. Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 456, 738-744 (2008).
42. Bohman T. Mathematics. Emergence of connectivity in networks. Science 323(5920), 1438-1439 (2009).
43. Wood SN. Statistical inference for noisy nonlinear ecological dynamic systems. Nature 466(7310), 1102-1104 (2010).
44. Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype- phenotype-based personalized cancer care. Expert Rev. Mol. Diagn. 10(1), 33-48 (2010)